Sun Pharma: Why consider the stock?
Sun Pharma had deployed significant resources in gaining access to specialty products in the past 6-7 years. For example in 2014, the company entered an In-licencing agreement with Merck for Tildrakizumab, a biologic for psoriasis. Further, their clinical development, commercialisation and development of a future R&D pipeline of specialty products.
As of FY21, the company has 12 specialty products (commercialised) that contribute to about 11% of the company’s revenue.
Apart from specialty products, the company also branded generics, complex generics, pure generics, and APIs.
Sun Pharma’s investment in R&D (research and development) has helped the company establish its market presence. This is not only in India but also in international markets. An increase in access to healthcare globally
Click here